UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 27, 2017
Commission File #: 000-53723
TAURIGA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Florida
(State or other jurisdiction of incorporation)
30-0791746
(IRS Employer Identification Number)
555 Madison Avenue, 5th Floor
New York, NY
(Address of principal executive office)
Tel: (917) 796-9926
(Registrant’s telephone number)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Item 7.01 Regulation FD Disclosure
On December 27, 2017, Tauriga Sciences, Inc. (the “Company”) announced that the Company intends on purchasing $25,000 of the crypto currency called Groestlcoin (Crypto Currency Code: GRS). This purchase will be funded by the Company’s available cash and is expected to be completed over the next ninety (90) days in several distinct tranches over multiple dates.
On January 3, 2018, the Company completed the purchase of the first tranche of Groestlcoin in an aggregate amount of $10,000 for 3,805.835 Groestlcoin (Price per Unit: $2.63).
The press release announcing the above-described transaction and planned purchase is furnished as Exhibit 99.1 to this current report on Form 8-K.
| Item 9.01 | Exhibits Statements and Exhibits |
| (d) | Exhibits |
| Exhibit Number | Description | |
| 99.1 | Press Release, dated December 27, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 4, 2018
| TAURIGA SCIENCES, INC. | ||
| By: | /s/ Seth M. Shaw | |
| Seth M. Shaw | ||
| Chief Executive Officer | ||
Tauriga Sciences, Inc. to Diversify $25,000 of its Balance Sheet Cash into Groestlcoin and Gain Exposure to the Crypto Currency Sector
NEW YORK, NY—(Marketwired - Dec 27, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments, today announced that the Company has decided to purchase, in total, $25,000 of the crypto currency called Groestlcoin (Crypto Currency Code: GRS). This $25,000 aggregate purchase will be funded by the Company’s available cash and is expected to be completed over the next 90 days (this $25,000 purchase will occur in several distinct tranches on several distinct dates).
As of December 27, 2017, the Company has already transferred $10,000 to San Francisco based digital currency exchange COINBASE — to facilitate the purchase of the initial tranche of Groestlcoin. The Company anticipates that the purchase of this first Groestlcoin tranche will be completed by January 10, 2018. Once this initial tranche purchase is complete, the Company will notify shareholders on Form 8K to disclose the specifics of the completed transaction(s).
The Company has been evaluating multiple opportunities to gain a degree of exposure to the crypto currency market sector. The Company has opted to acquire $25,000 of Groestlcoin, due to the comparatively low current market capitalization of Groestlcoin and the specific features of this crypto currency that Tauriga believes differentiates it from the more than 1,000 other choices (available to the Company for gaining exposure to this sector).
Tauriga’s Chief Executive Officer, Seth M. Shaw expressed, “The Company has decided to provide its shareholders with a degree of exposure to the crypto currency sector. The Company believes that it has accomplished this corporate aim in both a measured and responsible manner. After carefully evaluating a number of crypto currencies, which incorporate block chain technology, the Company believes that Groestlcoin has incorporated some important features that differentiates it from other crypto currencies. The Company also understands that any exposure to this sector, at this point in time, carries a high level of inherent risk. Therefore, the Company has limited its downside to $25,000 but is hopeful that this exposure to Groestlcoin will ultimately be successful for its shareholders.”
Please see the two below links for additional information on Groestlcoin:
| 1) | https://www.groestlcoin.org | |
| 2) | https://coinmarketcap.com/currencies/groestlcoin/ |
The long term strategic plan for Tauriga Sciences Inc. remains as disclosed in the Company’s press release dated November 15, 2017; to consummate one or more significant acquisition and/or licensing transactions during the calendar year 2018 to both restore and create long term shareholder value.
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (OTC PINK: TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is presently focused on its upcoming contemplated launch of a Cupacu Butter based lip balm product branded under the name: Herman. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. Please visit the Corporate Website at www.tauriga.com
NON SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation: expectations, expects, anticipates, believes, hopes, beliefs, plans and objectives regarding the development, use and marketability of products as well as the attainment of certain corporate goals and milestones (i.e. SEC Periodic Filings, Filing of Proxies, etc.). Such forward-looking statements are based on present circumstances and on Tauriga’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions and other factors over which Tauriga has little or no control. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by Tauriga with the Securities and Exchange Commission.
CONTACT INFORMATION
Tauriga Sciences Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
www.tauriga.com